253 related articles for article (PubMed ID: 19738009)
1. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model.
Vidaillac C; Leonard SN; Rybak MJ
Antimicrob Agents Chemother; 2009 Nov; 53(11):4712-7. PubMed ID: 19738009
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the "seesaw effect".
Werth BJ; Steed ME; Kaatz GW; Rybak MJ
Antimicrob Agents Chemother; 2013 Jun; 57(6):2664-8. PubMed ID: 23545533
[TBL] [Abstract][Full Text] [Related]
3. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of
Kebriaei R; Rice SA; Stamper KC; Rybak MJ
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670436
[TBL] [Abstract][Full Text] [Related]
4. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.
Bhalodi AA; Hagihara M; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2014; 58(2):672-7. PubMed ID: 24217694
[TBL] [Abstract][Full Text] [Related]
5. Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model.
Singh R; Almutairi M; Alm RA; Lahiri SD; San Martin M; Chen A; Ambler JE
J Antimicrob Chemother; 2017 Oct; 72(10):2796-2803. PubMed ID: 29091195
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of human-simulated epithelial lining fluid exposures of ceftaroline, ceftriaxone, and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus.
MacVane SH; So W; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2014 Dec; 58(12):7520-6. PubMed ID: 25288076
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.
Steed M; Vidaillac C; Rybak MJ
Antimicrob Agents Chemother; 2011 Jul; 55(7):3522-6. PubMed ID: 21576449
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration.
da Costa TM; Cuba GT; Morgado PGM; Nicolau DP; Nouér SA; Dos Santos KRN; Kiffer CRV
BMC Infect Dis; 2020 Jan; 20(1):74. PubMed ID: 31973753
[TBL] [Abstract][Full Text] [Related]
9. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
Smith JR; Barber KE; Hallesy J; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.
MacGowan AP; Noel AR; Tomaselli S; Bowker KE
Antimicrob Agents Chemother; 2013 Jun; 57(6):2451-6. PubMed ID: 23459495
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
Werth BJ; Barber KE; Ireland CE; Rybak MJ
Antimicrob Agents Chemother; 2014 Jun; 58(6):3177-81. PubMed ID: 24663016
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.
Barber KE; Smith JR; Ireland CE; Boles BR; Rose WE; Rybak MJ
Antimicrob Agents Chemother; 2015 Aug; 59(8):4497-503. PubMed ID: 25987623
[TBL] [Abstract][Full Text] [Related]
13. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates.
Vidaillac C; Leonard SN; Rybak MJ
Int J Antimicrob Agents; 2010 Jun; 35(6):527-30. PubMed ID: 20346632
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of novel anti-MRSA cephalosporins and comparator antimicrobial agents against staphylococci involved in prosthetic joint infections.
Isnard C; Dhalluin A; Malandain D; Bruey Q; Auzou M; Michon J; Giard JC; Guérin F; Cattoir V
J Glob Antimicrob Resist; 2018 Jun; 13():221-225. PubMed ID: 29421316
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
16. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
Smith JR; Yim J; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
[TBL] [Abstract][Full Text] [Related]
17. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.
Werth BJ; Sakoulas G; Rose WE; Pogliano J; Tewhey R; Rybak MJ
Antimicrob Agents Chemother; 2013 Jan; 57(1):66-73. PubMed ID: 23070161
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
Saravolatz L; Pawlak J; Johnson L
Antimicrob Agents Chemother; 2010 Jul; 54(7):3027-30. PubMed ID: 20404122
[TBL] [Abstract][Full Text] [Related]
19. Ceftaroline-heteroresistant Staphylococcus aureus.
Saravolatz SN; Martin H; Pawlak J; Johnson LB; Saravolatz LD
Antimicrob Agents Chemother; 2014 Jun; 58(6):3133-6. PubMed ID: 24637680
[TBL] [Abstract][Full Text] [Related]
20. Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model.
Zhanel GG; Rossnagel E; Nichol K; Cox L; Karlowsky JA; Zelenitsky S; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2011 Jun; 66(6):1301-5. PubMed ID: 21429940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]